<DOC>
	<DOCNO>NCT02451839</DOCNO>
	<brief_summary>For public health purpose disability become increasingly important outcome measure . Despite , data effectiveness adalimumab disability outcome patient Immune-Mediated Inflammatory Diseases ( IMIDs ) , particularly Phase IV set . There even less data available New Zealand , opportunity participate major extent large , multinational , Phase III pivotal study adalimumab IMIDs . The World Health Organisation Disability Assessment Schedule ( WHODAS ) 2.0 simple , validate , free easy-to-use generic assessment instrument health disability . It applicable across culture , adult population . It responsive measure show difference treatment make . Results study effect adalimumab WHODAS score Patient-Reported Outcomes ( PRO ) work activity well-being interest variety stakeholder healthcare system include patient , healthcare practitioner payer .</brief_summary>
	<brief_title>An ObserVatIonal STudy Effectiveness AdaLimumab Health Disability Outcomes New Zealand Patients With Immune-Mediated InflammaTorY Diseases ( VITALITY )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Patients diagnosis rheumatoid arthritis , Crohn 's disease psoriasis make decision physician commence treatment adalimumab accordance routine medical practice approve adalimumab New Zealand data sheet . Patients evaluate tuberculosis risk factors/exposure active/latent tuberculosis infection ( per local requirement accord approve adalimumab New Zealand Datasheet ) . Subject voluntarily sign date informed consent form prior studyspecific procedure . Previous treatment adalimumab . Previous treatment biologic . Severe infection include sepsis , active tuberculosis opportunistic infection . Moderate severe heart failure ( New York Heart Association Class II/III ) . Concurrent administration anakinra . Hypersensitivity adalimumab excipients . Any condition opinion investigator would compromise subject 's wellbeing ability perform study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Adalimumab</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Crohn Disease</keyword>
	<keyword>Patient Outcome Assessment</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Global Health</keyword>
	<keyword>Arthritis , Rheumatoid</keyword>
</DOC>